Modulation of AAV9 Galactose Binding Yields Novel Gene Therapy Vectors and Predicts Cross-Species Differences in Glycan Avidity

Hum Gene Ther. 2024 Sep;35(17-18):734-753. doi: 10.1089/hum.2024.050. Epub 2024 Aug 13.

Abstract

Effective use of adeno-associated viruses (AAVs) for clinical gene therapy is limited by their propensity to accumulate in and transduce the liver. This natural liver tropism is associated with severe adverse events at the high doses that can be necessary for achieving therapeutic transgene expression in extrahepatic tissues. To improve the safety and cost of AAV gene therapy, capsid engineering efforts are underway to redirect in vivo AAV biodistribution away from the liver toward disease-relevant peripheral organs such as the heart. Building on previous work, we generated a series of AAV libraries containing variations at three residues (Y446, N470, and W503) of the galactose-binding pocket of the AAV9 VP1 protein. Screening of this library in mice identified the XRH family of variants (Y446X, N470R, and W503H), the strongest of which, HRH, exhibited a 6-fold reduction in liver RNA expression and a 10-fold increase in cardiac RNA expression compared with wild-type AAV9 in the mouse. Screening of our library in a nonhuman primate (NHP) revealed reduced performance of AAV9 and two closely related vectors in the NHP liver compared with the mouse liver. Measurement of the galactose-binding capacity of our library further identified those same three vectors as the only strong galactose binders, suggesting an altered galactose presentation between the mouse and NHP liver. N-glycan profiling of these tissues revealed a 9% decrease in exposed galactose in the NHP liver compared with the mouse liver. In this work, we identified a novel family of AAV variants with desirable biodistribution properties that may be suitable for targeting extrahepatic tissues such as the heart. These data also provide important insights regarding species- and tissue-specific differences in glycan presentation that may have implications for the development and translation of AAV gene therapies.

Keywords: adeno-associated virus (AAV); glycan; glycomics; nonhuman primate (NHP); transduction; translational.

MeSH terms

  • Animals
  • Capsid Proteins / genetics
  • Capsid Proteins / metabolism
  • Dependovirus* / genetics
  • Galactose* / metabolism
  • Genetic Therapy* / methods
  • Genetic Vectors* / genetics
  • Humans
  • Liver / metabolism
  • Mice
  • Polysaccharides* / metabolism
  • Species Specificity
  • Transduction, Genetic

Substances

  • Galactose
  • Polysaccharides
  • Capsid Proteins